Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/15/2005US20050277648 Use of PDE IV inhibitors to treat angiogenesis
12/15/2005US20050277647 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
12/15/2005US20050277646 N-[4-({5-(4-fluorophenyl)-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}oxy)-1,3-benzothiazol-2-yl]acetamide; vanilloid (capsaicin) receptor antagonist/agonist; antiinflammatory, analgesic, antiarthritis, antirheumatic; diseases involving sensory nerve function
12/15/2005US20050277645 Sleep inducing compounds and methods relating thereto
12/15/2005US20050277644 Pyridine analogs as C5a antagonists
12/15/2005US20050277643 N-(4-tert-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yl]-amine; antiinflammatory agents treating pain, inflammation, traumatic injury, arthritis, Parkinson's disease, Alzheimer's disease, stroke, asthma, myocardial infarction
12/15/2005US20050277641 Nitrogen compounds such as 4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-1,3,5-triazin-2-yl]amino]benzonitrile, used for prophylaxis of viral diseases such as human immunodeficiency virus
12/15/2005US20050277640 Pyrimidine derivatives for treatment of hyperproliferative disorders
12/15/2005US20050277639 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
12/15/2005US20050277638 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
12/15/2005US20050277636 Lowering intraocular pressure with S)-2-(8,9-dihydro-9-methyl-7H-[1,4]oxazino[2,3-g]indazol-1-yl)-1-methylethylamine fumarate
12/15/2005US20050277635 Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds
12/15/2005US20050277634 Liquid composition for veterinary medicine and process for the preparation and use thereof
12/15/2005US20050277633 E.g., rifamycin S derivatives such as 2',2'-Dimethyl-3,4-piperazinorifamycin S and Spiro[N-methyl-piperidine-3,4-piperazinorifamycin S; treating bacterial infections, especially those caused by rifamycin-resistant bacteria
12/15/2005US20050277632 2-Hydroxyethylamines 2-substituted by a hydroxy-N-heterocycle and N-substituted by an omega-phenyl-1,1-dimethylalkyl group: 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one; betamimetics
12/15/2005US20050277629 Methods for the treatment of synucleinopathies (Lansbury)
12/15/2005US20050277627 Colchinol derivatives as vascular damaging agents
12/15/2005US20050277626 Methods and compositions for treatment of nicotine dependence and dementias
12/15/2005US20050277625 Estriol and estetrol prodrugs
12/15/2005US20050277624 Use of corticosteroids alone or in conjunction with nutritional therapy to reduce stress in animals
12/15/2005US20050277623 Treatment for averting or delaying premature delivery
12/15/2005US20050277622 for treatment of viral infection, tumor, AIDS, fever, ache, and constipation, improvement of immunity, kidney function, neural regulation and physical recovery
12/15/2005US20050277621 For administration of bisphosphonates, e.g., alendronate, clodronate, etidronate, ibandronate, incadronate, minodronate, neridronate, olpadronate, pamidronate, risedronate, tiludronate, zoledronate, EB1053, or YH529, to treat various kinds of cancer
12/15/2005US20050277620 Aryl phosphate derivatives of d4T
12/15/2005US20050277617 Comprises an amino sugar and trehalose
12/15/2005US20050277616 Thymine nucleosides with anti-hepatitis B virus activity
12/15/2005US20050277615 Pharmaceutical compositions having anti-inflammatory activity
12/15/2005US20050277614 Methods for modulating the axonal outgrowth of central nervous system neurons
12/15/2005US20050277609 Immunostimulatory nucleic acid molecules
12/15/2005US20050277606 Administering by direct injection into heart an expression vector comprising a nucleic acid sequence encoding AOP-1 operably linked to a promoter, wherein expression of nucleic acid sequence within cells of heart enhances production of AOP-1, protecting against myocardial cell death
12/15/2005US20050277604 Immunostimulatory nucleic acid molecules
12/15/2005US20050277602 Methods employing agonists of P38 map kinase for the treatment of asthma
12/15/2005US20050277601 Anticancer biangeloyl saponins
12/15/2005US20050277600 Compositions and methods of use of dimer digallates
12/15/2005US20050277598 Method for improving ventilatory efficiency
12/15/2005US20050277596 Use of lacosamide; motor neuron disorders
12/15/2005US20050277585 Combinations of immunosupressive agents for the treatment or prevention of graft rejections
12/15/2005US20050277584 Pharmaceutical compositions comprising cyclosporins
12/15/2005US20050277581 prolonged serum half-life to permit treatment regimens of about once every 5-7 days or longer, while retaining antibacterial properties in vivo
12/15/2005US20050277579 Compositions for affecting weight loss
12/15/2005US20050277577 Compositions and methods for treating diverticular disease
12/15/2005US20050277575 Therapeutic compositions and methods for treating diseases that involve angiogenesis
12/15/2005US20050277573 Disinfectant
12/15/2005US20050277171 5Z,7E-3 beta ,11 alpha -dihydroxy-9,10-secopregna-5,7,10(19)trien-20-one; from enzymatically hydroxylating the vitamin D3-like compound
12/15/2005US20050277118 Methods for identifying subjects at risk of melanoma and treatments thereof
12/15/2005US20050276974 Phospholipid-free, having a D50 particle size of less than 500 nm, andhaving a surface stabilizer; improved pharmacokinetic profiles and reduced fed/fasted variability
12/15/2005US20050276893 Method for producing fat and/or solids from beans and compositions containing polyphenols
12/15/2005US20050276870 Theobromine, L-phenylalanine, nicotinamide adenine dinucleotide, cayenne pepper, and green tea; human dietary supplement to increase energy; nutraceuticals
12/15/2005US20050276867 Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
12/15/2005US20050276866 Combination comprising a CDK inhibitor and cisplatin
12/15/2005US20050276865 Peroxide compounds for the prevention and treatment of sexual dysfunction in humans
12/15/2005US20050276859 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
12/15/2005US20050276855 Composition and method using local application of lipophilic lathyrogens sustained release formulations
12/15/2005US20050276854 Bioimplant formulation
12/15/2005US20050276853 Chronotherapeutic dosage forms and methods of treatment using chronotherapy
12/15/2005US20050276852 Sustained release formulations of guaifenesin and additional drug ingredients
12/15/2005US20050276851 Sustained release aminopyridine composition
12/15/2005US20050276850 Controlled release sodium valproate formulation
12/15/2005US20050276848 Sustained release neutralized divalproex sodium
12/15/2005US20050276847 Oral delivery system
12/15/2005US20050276844 Bioavailable compositions of metaxalone and processes for producing the same
12/15/2005US20050276843 An aerosol drug delivery device containing PTH, cyclodextrin, and didecanoylphophatidylcholine that provides droplets of 25 to 700 microns in size; improved bioavailability; osteoporosis
12/15/2005US20050276841 Biodegradable drug-polymer delivery system
12/15/2005US20050276839 Appetite satiation and hydration beverage
12/15/2005US20050276838 Composition and method for viral inhibition
12/15/2005US20050276837 Controlled release bioactive agent delivery device
12/15/2005US20050276832 Topical compositions and uses thereof for treating aquatic animals subjected to disinfection and vaccination
12/15/2005US20050276830 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
12/15/2005US20050276824 Pharmaceutical emulsions for retroviral protease inhibitors
12/15/2005US20050276810 Cis-4-hydroxy-L-proline (CHP) together with bevacizumab for targeted treatment of cell proliferative disorders
12/15/2005US20050276804 Method for preventing or treating cardiac hypertrophy
12/15/2005US20050276803 Method for augmenting B cell depletion
12/15/2005US20050276798 with a histidine buffer and maltose; anti-HIV; higher concentrations, are storage stable, compatible with lyophilization, and safe to administer by intravenous injection
12/15/2005US20050276795 Chemotherapeutic and prophylactic pharmaceutical compositions
12/15/2005US20050276794 Composition and method for improving pancreatic islet cell survival
12/15/2005US20050276789 Immunostimulatory oligonucleotides and uses thereof
12/15/2005US20050276783 Polypeptides with the capacity to entrap drugs and release them in a controlled way
12/15/2005US20050276781 Molecularly imprinted phosphate binders for therapeutic use
12/15/2005US20050276765 Preventing skin damage
12/15/2005US20050276764 Topical use of bis-arylimidazo[1,2-a]thiolane derivatives
12/15/2005US20050276762 Topical compositions containing 5'-adenosine-diphosphate ribose
12/15/2005US20050276756 Compositions as adjuvants to improve immune responses to vaccines and methods of use
12/15/2005US20050274671 Method for preparing a compound of interaction of active substances with a porous support using supercritical fluid
12/15/2005US20050274391 Means for weaning people off smoking and alcohol
12/15/2005DE10210195B4 Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz Using 1,3-diazaspiro [4,5] decane-2,4-dithione for treating pain
12/15/2005DE102004026679A1 Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat Hormonal contraceptive containing a combination of ethinyl estradiol and chlormadinone
12/15/2005DE102004026670A1 Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat Hormonal contraceptive containing a combination of ethinyl estradiol and chlormadinone
12/15/2005DE102004026669A1 Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels Use of a combination of ethinyl estradiol and chlormadinone acetate in the manufacture of a medicament
12/15/2005DE102004026026A1 New 2-(hetero)aryl-tetrahydroquinoline derivatives and 1,2,3,4-tetrahydro-1,5-naphthyridine derivatives are mitotic motor protein Eg5 inhibitors used as anticancer agents for treating carcinoma or leukemia
12/15/2005DE102004025791A1 Chromanol-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer Chromanol derivatives, a process for their preparation and their use as anti-inflammatories
12/15/2005DE102004025071A1 Producing 1,4-diphenylazetidinone derivatives useful as cholesterol resorption inhibitors from protected beta-substituted amino amides comprises using a quaternary phosphonium salt catalyst
12/15/2005DE102004022765A1 Verfahren zur Herstellung von Monoarylpiperazinen A process for preparing Monoarylpiperazinen
12/15/2005DE10157260B4 Streichfähige Salbe mit Ozoniden und Peroxiden von Fettsäuren oder deren Estern Spreadable ointment with ozonides and peroxides of fatty acids or their esters
12/15/2005CA2578806A1 Oral formulations of paricalcitol
12/15/2005CA2572451A1 Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature
12/15/2005CA2569881A1 Compositions comprising nebivolol
12/15/2005CA2569520A1 Egfr mutations
12/15/2005CA2569514A1 Oral preparations and process for production thereof
12/15/2005CA2569508A1 Selenium-enriched biomass, method for preparing thereof and probiotic and nutraceutical products including said biomass
12/15/2005CA2569475A1 Compositions containing opioid antagonists
1 ... 4433 4434 4435 4436 4437 4438 4439 4440 4441 4442 4443 4444 4445 4446 4447 4448 4449 4450 4451 4452 4453 ... 7860